Limits...
Eurocan Platform meeting: European recommendations for biomarker-based chemoprevention trials.

Cairns L - Ecancermedicalscience (2014)

Bottom Line: Chemoprevention or the now more preferred 'cancer prevention' is the long-term administration of a biological or chemical agent to reduce the risk of cancer.This approach has long been active in individuals at high risk of developing breast or colon cancer.The aim of this expert meeting was to review the current status of the field of cancer prevention and potential, emerging biomarkers specifically focusing on breast, colon, and lung cancer but also with sessions on ovary and prostate.

View Article: PubMed Central - PubMed

Affiliation: Science Editor, e cancermedicalscience, European Institute of Oncology, Via Ripamonti 435, Milan 20141, Italy.

ABSTRACT
Chemoprevention or the now more preferred 'cancer prevention' is the long-term administration of a biological or chemical agent to reduce the risk of cancer. This approach has long been active in individuals at high risk of developing breast or colon cancer. The aim of this expert meeting was to review the current status of the field of cancer prevention and potential, emerging biomarkers specifically focusing on breast, colon, and lung cancer but also with sessions on ovary and prostate.

No MeSH data available.


Related in: MedlinePlus

Genes which predispose to an increased risk of breast cancer [4–9].
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4263526&req=5

figure1: Genes which predispose to an increased risk of breast cancer [4–9].

Mentions: Jack Cuzick started the meeting discussing the challenges in developing and validating biomarkers for cancer prevention. Breast cancer is escalating exponentially, and by 2020, there will be around 2 million new cases per year. There is an urgent need to identify high-risk populations and to identify minimally toxic preventative therapy. He discussed the known risk factors associated with breast cancer: family history, reproductive/hormonal factors and benign pathology. He touched on the genes that can predict risk, including the well-established BRCA1/2 as well as other more recent discoveries (Figure 1). He mentioned the importance of mammographic density as an individual risk factor, and this will be discussed later. Single nucleotide polymorphisms, frequently called SNPs, are the most common type of genetic variation among people and can be useful for refining risk estimates in women with phenotypic risk factors for breast cancer. Cuzick presented the results from two randomized tamoxifen prevention trials in which an SNP panel was included to refine risk estimates in women at high risk of breast cancer. However, the SNP profiles did not appear to predict benefit from tamoxifen. He pointed out that there is still a need for biomarkers for late recurrence in breast cancer. Finally, he discussed the need for a better biomarker than PSA for prostate cancer and discussed the use of cell cycle progression genes CCP, i.e., genes which encode products that are required during cell cycle progression. The predicted risk of death from prostate cancer based on the combined cell cycle clinical (CCR) score and the CAPRA score can be calculated.


Eurocan Platform meeting: European recommendations for biomarker-based chemoprevention trials.

Cairns L - Ecancermedicalscience (2014)

Genes which predispose to an increased risk of breast cancer [4–9].
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4263526&req=5

figure1: Genes which predispose to an increased risk of breast cancer [4–9].
Mentions: Jack Cuzick started the meeting discussing the challenges in developing and validating biomarkers for cancer prevention. Breast cancer is escalating exponentially, and by 2020, there will be around 2 million new cases per year. There is an urgent need to identify high-risk populations and to identify minimally toxic preventative therapy. He discussed the known risk factors associated with breast cancer: family history, reproductive/hormonal factors and benign pathology. He touched on the genes that can predict risk, including the well-established BRCA1/2 as well as other more recent discoveries (Figure 1). He mentioned the importance of mammographic density as an individual risk factor, and this will be discussed later. Single nucleotide polymorphisms, frequently called SNPs, are the most common type of genetic variation among people and can be useful for refining risk estimates in women with phenotypic risk factors for breast cancer. Cuzick presented the results from two randomized tamoxifen prevention trials in which an SNP panel was included to refine risk estimates in women at high risk of breast cancer. However, the SNP profiles did not appear to predict benefit from tamoxifen. He pointed out that there is still a need for biomarkers for late recurrence in breast cancer. Finally, he discussed the need for a better biomarker than PSA for prostate cancer and discussed the use of cell cycle progression genes CCP, i.e., genes which encode products that are required during cell cycle progression. The predicted risk of death from prostate cancer based on the combined cell cycle clinical (CCR) score and the CAPRA score can be calculated.

Bottom Line: Chemoprevention or the now more preferred 'cancer prevention' is the long-term administration of a biological or chemical agent to reduce the risk of cancer.This approach has long been active in individuals at high risk of developing breast or colon cancer.The aim of this expert meeting was to review the current status of the field of cancer prevention and potential, emerging biomarkers specifically focusing on breast, colon, and lung cancer but also with sessions on ovary and prostate.

View Article: PubMed Central - PubMed

Affiliation: Science Editor, e cancermedicalscience, European Institute of Oncology, Via Ripamonti 435, Milan 20141, Italy.

ABSTRACT
Chemoprevention or the now more preferred 'cancer prevention' is the long-term administration of a biological or chemical agent to reduce the risk of cancer. This approach has long been active in individuals at high risk of developing breast or colon cancer. The aim of this expert meeting was to review the current status of the field of cancer prevention and potential, emerging biomarkers specifically focusing on breast, colon, and lung cancer but also with sessions on ovary and prostate.

No MeSH data available.


Related in: MedlinePlus